Scavenging Free Radicals by Low-Dose Carvedilol Prevents Redox-Dependent Ca2+ Leak Via Stabilization of Ryanodine Receptor in Heart Failure

Journal of the American College of Cardiology

Volumn 49, Issue 16, 2007, Pages 1722-1732

  Mochizuki, Mamoru ^a   Yano, Masafumi ^a   Oda, Tetsuro ^a   Tateishi, Hiroki ^a   Kobayashi, Shigeki ^a   Yamamoto, Takeshi ^a   Ikeda, Yasuhiro ^a   Ohkusa, Tomoko ^a   Ikemoto, Noriaki ^b,c   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CARVEDILOL; COUMARIN DERIVATIVE; FREE RADICAL; GLYCINE; METHYLCOUMARIN ACETATE; PEPTIDE DPC10; PROLINE; REACTIVE OXYGEN METABOLITE; RYANODINE RECEPTOR; RYANODINE RECEPTOR 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CATECHOLAMINE RELEASE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOG; GENE MUTATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PACING; HEART VENTRICLE TACHYCARDIA; LOW DRUG DOSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CALCIUM; CARBAZOLES; CARDIAC OUTPUT, LOW; DOGS; FREE RADICALS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROPANOLAMINES; REACTIVE OXYGEN SPECIES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 34247150261     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.01.064     Document Type: Article

References (15)

1. Ikemoto N., and Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci 7 (2002) d671-d683
2. Yano M., Yamamoto T., Ikemoto N., and Matsuzaki M. Abnormal ryanodine receptor function in heart failure. Pharmacol Ther 107 (2005) 377-391
3. Oda T., Yano M., Yamamoto T., et al. Defective regulation of inter-domain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 111 (2005) 3244-3254
4. Yano M., Kobayashi S., Kohno M., et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107 (2003) 477-484
5. Meissner G. Regulation of mammalian ryanodine receptors. Front Biosci 7 (2002) d2072-d2080
6. Yano M., Okuda S., Oda T., et al. Correction of defective inter-domain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 112 (2005) 3633-3643
7. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
8. 2+ leak through ryanodine receptor in heart failure. Circulation 102 (2000) 2131-2136
9. Yamamoto T., and Ikemoto N. Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem Biophys Res Commun 291 (2002) 1102-1108
10. Marx S.O., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365-376
11. Kosower N.S., and Kosower E.M. Thiol labeling with bromobimanes. Methods Enzymol 143 (1987) 76-84
12. Xu L., Eu J.P., Meissner G., and Stamler J.S. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279 (1998) 234-237
13. Nakamura K., Fushimi K., Kouchi H., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98 (1998) 794-799
14. Gwathmey J.K., Kim C.S., Hajjar R.J., Khan F., DiSalvo T.G., Matsumori A., and Bristow M.R. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol 276 (1999) H1678-H1690
15. Hori M., Sasayama S., Kitabatake A., et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147 (2004) 324-330